EU
Lilly and Boehringer diabetes biosimilar sees EU approval
September 11, 2014Sales and Marketing Boehringer, EU, European Commission, Lantus, Sanofi, diabetes, lilly
Lilly and Boehringer Ingelheim’s insulin glargine product has been shown the green light by the European Commission (EC). The copycat …
MHRA leads social media drug safety initiative
September 8, 2014Medical Communications, Sales and Marketing EFPIA, EU, MHRA, social media, web-radr
The MHRA has announced that it is to lead European medicines regulators, academics and pharma in a three-year project to …
Europe warned over cancer research risk
July 27, 2014Medical Communications, Research and Development, Sales and Marketing ESMO, EU, Macmillan, data
A leading European doctors’ group is warning that new data protection rules could make cancer research ‘impossible’ whilst also adding …
AbbVie hep C treatment fast-tracked
June 18, 2014Research and Development, Sales and Marketing AbbVie, Abbott, EMA, EU, Gilead, HCV, hep C, sovaldi
The European regulator is to fast-track AbbVie’s oral, interferon-free treatment for adults with chronic genotype 1 (GT1) hepatitis C virus …
InterMune drops EMA lawsuit over data release
June 10, 2014Research and Development, Sales and Marketing EMA, EU, Esbriet, Goldacre, InterMune, alltrials, lung
InterMune has ended a year-long legal spat with the European Medicines Agency over the potential release of data for its …
EU looks at eye drug allegations
May 8, 2014Sales and Marketing EU, Lucentis, Novartis, Roche, avastin, offlabel
European Union regulators are considering whether they need to take any action over the recent allegations of anti-competitiveness involving Roche …
EMA to conduct major review into testosterone drugs
April 14, 2014Research and Development, Sales and Marketing EMA, EU, Europe, heart, testosterone
The European Medicines Agency has started a review of testosterone-containing medicines as concerns grow that they may increase the risk …
EU votes for trial transparency
April 3, 2014Research and Development, Sales and Marketing ABPI, EFPIA, EU, Goldacre, UK, alltrials, transparency, willmott
Europe took a decisive step toward forcing pharma to open up its clinical trial data last night, after the EU …
CHMP recommends Jardiance
March 24, 2014Research and Development, Sales and Marketing Boehringer, CHMP, EU, diabetes, jardiance, lilly
Boehringer Ingelheim and Eli Lilly’s type 2 diabetes treatment Jardiance is among nine medicines which the Committee for Medicinal Products …
Data transparency debate: Europe decides its future
March 24, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EFPIA, EMA, EU, Goldacre, NHS, alltrials, european, transparency
Transparency became a major issue in 2013 as various new pressure groups sprung up with the shared aim of forcing …
Europe: TB treatment ‘far below’ target
March 19, 2014Research and Development, Sales and Marketing EU, MDR TB, TB, WHO, tuberculosis
European countries are still not getting to grips with the diagnosis and treatment of tuberculosis, according to a new report …
EFPIA targets MEPs in social media campaign
March 17, 2014Medical Communications, Sales and Marketing EFPIA, EU, bergstrom, pharma summit, social media
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has launched a social media campaign aimed at MEPs. With ten …
Biogen Idec’s MS drug gets European approval
February 4, 2014Manufacturing and Production, Sales and Marketing Aubagio, Biogen IDEC, EU, MS, gilenya, tecdifera
Biogen Idec’s oral multiple sclerosis drug Tecfidera has won approval in Europe as a first-line treatment for people with relapsing-remitting …
Teva’s Great White Hope knocked back by Europe
January 27, 2014Sales and Marketing CHMP, EU, MS, Nerventra, Teva
The drug designed to be a follow-up to Teva’s wildly successful Copaxone has been hit by rejection in Europe, leaving …
NICE recommends Aubagio
January 22, 2014Sales and Marketing Aubagio, EU, FDA, NICE, Sanofi, gilenya
NICE has recommended Genzyme’s multiple sclerosis pill Aubagio for use on the NHS. In final guidance the watchdog said Aubagio …
Latest content
